The COVAIL trial reveals that neutralizing antibody titers correlate with COVID-19 risk reduction after mRNA boosters. Learn how this impacts vaccine strategies against emerging variants.
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
Robert F. Kennedy Jr, the nominee for secretary of HHS, has made promises about the status of his stake in antivaccine nonprofits and legal action against pharma companies as his confirmation hearing ...
The VE of the 2023-2024 COVID-19 vaccine in individuals with IC vs those without was 36% vs 51% at 7 to 59 days after vaccination and 1% vs 15% at 120 to 179 days. The Centers for Disease Control and ...
To effectively lower the risk of cervical cancer, it is crucial for vulnerable groups to receive the HPV vaccine and adopt other preventive measures. Vaccination at an early age – ideally before the ...
New Delhi: Noting the phase I clinical trial report presented by the vaccine major Serum Institute of India, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control ...